Wegovy dose increments: the facts behind the schedule

The myth that you need to rush through the increments

A common assumption is that the lower Wegovy doses are just marking time, a box-ticking exercise before the 'real' dose begins. That's worth addressing directly, because it leads some people to push through increments faster than intended, or to feel disappointed when 0.25 mg or 0.5 mg doesn't produce dramatic results on the scales.

The lower steps serve a clear purpose. Semaglutide slows how quickly the stomach empties food into the small intestine, and that effect is felt more intensely when the dose climbs quickly. Nausea, indigestion and fatigue (the most commonly reported early side effects) are significantly less likely when the body acclimates gradually. The four-week minimum at each increment isn't arbitrary; it reflects what the clinical trials showed about tolerability. The Wegovy overview on our site covers the full mechanism if you'd like more background on how the medicine works.

Weight loss does begin during the escalation phase for most people, just more modestly. Expecting the 0.25 mg pen to perform like the 2.4 mg maintenance dose sets an unfair benchmark. The goal of those first months is to reach the therapeutic dose without your digestive system staging a protest.

How each increment is structured, and the 7.2 mg update worth knowing about

The licensed escalation for Wegovy runs: 0.25 mg for the first four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the standard maintenance dose. Each pen contains four pre-set weekly doses at a single strength, so you're not adjusting a dial, you simply move to the next pen at the right time, guided by your prescriber.

For dose and measurement detail beyond the summary here, the Wegovy measurements page goes into further depth. It's worth reading alongside this one if you want to understand exactly what each pen delivers.

The MHRA approved a higher maintenance option in early 2026: a 7.2 mg weekly dose, initially delivered as three 2.4 mg pens and subsequently via a dedicated single-dose 7.2 mg pen confirmed on 14 April 2026. That pen is licensed for adults with a BMI of 30 or above and is not used for the separate cardiovascular indication. Clinical trial data at 7.2 mg reported an average weight reduction of around 20.7% over 72 weeks, narrowing the gap with the highest tirzepatide doses. Specific dose availability at any stage is confirmed through clinical assessment, never assumed in advance.

If you're curious about the specific increment steps and what distinguishes each one, that page addresses them in detail.

When an increment stalls, and what to do about it

Some people find a particular step harder to tolerate than expected: persistent nausea, disrupted sleep, or a stomach that simply hasn't settled after a few weeks. The instinct is sometimes to push through anyway. The better move is to tell your prescriber.

It is clinically acceptable to stay at a given increment for longer than four weeks if side effects remain troublesome. It is not safe to skip a step in the opposite direction, jumping ahead to accelerate results puts the tolerability rationale in reverse. A prescriber can also review whether something in your current routine (timing of the injection, diet composition, hydration) is contributing to side effects. The guide on increasing semaglutide doses covers the practical considerations around these decisions.

For context on what to take alongside Wegovy to support your health during treatment, the supplements and Wegovy page is worth a read, including the specific question of iron, which comes up more often than you'd expect and has its own dedicated page.

If side effects feel unmanageable at any point, the NHS semaglutide guidance recommends seeking medical advice rather than discontinuing the medicine independently, abrupt stops and self-managed restarts both carry risks.

Cost and access: what the escalation means practically

Each Wegovy pen covers four weekly injections at a single dose strength, which means the escalation phase involves several different pen strengths before you settle at maintenance. That has a bearing on cost: you're not buying the same pen every month during the escalation. Understanding how the pricing structure works during that period is useful before you start.

The Wegovy price page explains how costs are structured across dose levels for private treatment in the UK, with honest context about what a legitimate private prescription includes. As a rough reference, UK private treatment prices have shifted notably since Eli Lilly's August 2025 list-price increase for Mounjaro affected the wider market, the Wegovy pricing landscape has moved similarly, and any headline figure you see online may not include the consultation, prescription or delivery.

At nume, one price covers the consultation, the prescription, the medicine and free next-working-day delivery. Your pen arrives via DPD in plain, unbranded packaging, no label telling the neighbours what's inside. The consultation itself is reviewed the same day by a real prescriber, not a piece of software. You can read more about our clinical team's approach on the clinical team profile. For a broader look at the weight-loss options we offer, the treatment overview is a good starting point.

If you'd like to check whether Wegovy might be clinically suitable for you, starting a free consultation is the straightforward next step.